Mouse Model of Human Ovarian Endometrioid Adenocarcinoma Based on Somatic Defects in the Wnt/β-Catenin and PI3K/Pten Signaling Pathways

Cancer Cell

Volumn 11, Issue 4, 2007, Pages 321-333

  Wu, Rong ^a   Hendrix Lucas, Neali ^a   Kuick, Rork ^a   Zhai, Yali ^a   Schwartz, Donald R ^a   Akyol, Aytekin ^a   Hanash, Samir ^a   Misek, David E ^a   Katabuchi, Hidetaka ^b   Williams, Bart O ^c   Fearon, Eric R ^a   Cho, Kathleen R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

CELLCYCLE

Indexed keywords

BETA CATENIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APC GENE; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; METASTASIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PTEN GENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

MURINAE; MUS;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; BETA CATENIN; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DISEASE MODELS, ANIMAL; EPITHELIUM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MUTATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; OVARY; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; WNT1 PROTEIN;

EID: 34047171574     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.02.016     Document Type: Article

References (63)

1. Altomare D.A., and Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24 (2005) 7455-7464
2. Amemiya S., Sekizawa A., Otsuka J., Tachikawa T., Saito H., and Okai T. Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability. Int. J. Gynaecol. Obstet. 86 (2004) 371-376
3. Anton M., and Graham F.L. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: A molecular switch for control of gene expression. J. Virol. 69 (1995) 4600-4606
4. Backman S.A., Stambolic V., Suzuki A., Haight J., Elia A., Pretorius J., Tsao M.S., Shannon P., Bolon B., Ivy G.O., and Mak T.W. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 29 (2001) 396-403
5. Baeza N., Weller M., Yonekawa Y., Kleihues P., and Ohgaki H. PTEN methylation and expression in glioblastomas. Acta Neuropathol. (Berl.) 106 (2003) 479-485
6. Bell D.A. Origins and molecular pathology of ovarian cancer. Mod. Pathol. 18 Suppl 2 (2005) S19-S32
7. Brabletz T., Hlubek F., Spaderna S., Schmalhofer O., Hiendlmeyer E., Jung A., and Kirchner T. Invasion and metastasis in colorectal cancer: Epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 179 (2005) 56-65
8. Brachtel E.F., Sanchez-Estevez C., Moreno-Bueno G., Prat J., Palacios J., and Oliva E. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am. J. Surg. Pathol. 29 (2005) 1322-1329
9. Bui T., and Thompson C.B. Cancer's sweet tooth. Cancer Cell 9 (2006) 419-420
10. Caduff R.F., Svoboda-Newman S.M., Bartos R.E., Ferguson A.W., and Frank T.S. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am. J. Surg. Pathol. 22 (1998) 319-326
11. Campbell I.G., and Thomas E.J. Endometriosis: Candidate genes. Hum. Reprod. Update 7 (2001) 15-20
12. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., Cristiano B.E., Pearson R.B., and Phillips W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64 (2004) 7678-7681
13. Catasus L., Bussaglia E., Rodrguez I., Gallardo A., Pons C., Irving J.A., and Prat J. Molecular genetic alterations in endometrioid carcinomas of the ovary: Similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum. Pathol. 35 (2004) 1360-1368
14. Cheng W., Liu J., Yoshida H., Rosen D., and Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat. Med. 11 (2005) 531-537
15. Connolly D.C., Bao R., Nikitin A.Y., Stephens K.C., Poole T.W., Hua X., Harris S.S., Vanderhyden B.C., and Hamilton T.C. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 63 (2003) 1389-1397
16. Cuatrecasas M., Villanueva A., Matias-Guiu X., and Prat J. K-ras mutations in mucinous ovarian tumors: A clinicopathologic and molecular study of 95 cases. Cancer 79 (1997) 1581-1586
17. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., and Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11 (2005) 63-70
18. Emami K.H., Nguyen C., Ma H., Kim D.H., Jeong K.W., Eguchi M., Moon R.T., Teo J.L., Kim H.Y., Moon S.H., et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proc. Natl. Acad. Sci. USA 101 (2004) 12682-12687
19. Enomoto T., Weghorst C.M., Inoue M., Tanizawa O., and Rice J.M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am. J. Pathol. 139 (1991) 777-785
20. Erzen M., Rakar S., Klancnik B., Syrjanen K., and Klancar B. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol. Oncol. 83 (2001) 100-108
21. Flesken-Nikitin A., Choi K.C., Eng J.P., Shmidt E.N., and Nikitin A.Y. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63 (2003) 3459-3463
22. Fukunaga M., Nomura K., Ishikawa E., and Ushigome S. Ovarian atypical endometriosis: Its close association with malignant epithelial tumours. Histopathology 30 (1997) 249-255
23. Gamallo C., Palacios J., Moreno G., Calvo de Mora J., Suarez A., and Armas A. beta-catenin expression pattern in stage I and II ovarian carcinomas: Relationship with beta-catenin gene Mutations, Clinicopathological features, and clinical outcome. Am. J. Pathol. 155 (1999) 527-536
24. Giordano T.J., Shedden K.A., Schwartz D.R., Kuick R., Taylor J.M.G., Lee N., Misek D.E., Greenson J.K., Kardia S.L.R., Beer D.G., Rennert G., Cho K.R., Gruber S.B., Fearon E.R., and Hanash S. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am. J. Pathol. 159 (2001) 1231-1238
25. Granville C.A., Memmott R.M., Gills J.J., and Dennis P.A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin. Cancer Res. 12 (2006) 679-689
26. Guppy A.E., Nathan P.D., and Rustin G.J. Epithelial ovarian cancer: A review of current management. Clin. Oncol. (R Coll Radiol) 17 (2005) 399-411
27. Han S.Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., Matsuno S., Kanamaru R., and Ishioka C. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res. 60 (2000) 3147-3151
28. Ichikawa Y., Nishida M., Suzuki H., Yoshida S., Tsunoda H., Kubo T., Uchida K., and Miwa M. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 54 (1994) 33-35
29. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., Yang Q., Bennett C., Harada Y., Stankunas K., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126 (2006) 955-968
30. Janssens N., Janicot M., and Perera T. The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest. New Drugs 24 (2006) 263-280
31. Kato H., Kato S., Kumabe T., Sonoda Y., Yoshimoto T., Kato S., Han S.Y., Suzuki T., Shibata H., Kanamaru R., and Ishioka C. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin. Cancer Res. 6 (2000) 3937-3943
32. Kildal W., Risberg B., Abeler V.M., Kristensen G.B., Sudbo J., Nesland J.M., and Danielsen H.E. beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: A study in 253 patients. Eur. J. Cancer 41 (2005) 1127-1134
33. Kolasa I.K., Rembiszewska A., Janiec-Jankowska A., Dansonka-Mieszkowska A., Lewandowska A.M., Konopka B., and Kupryjanczyk J. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol. Oncol. 103 (2006) 692-697
34. Larue L., and Bellacosa A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24 (2005) 7443-7454
35. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., Bruseo C., Wood A.W., and Shivdasani R.A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5 (2004) 91-102
36. Moreno-Bueno G., Gamallo C., Perez-Gallego L., de Mora J.C., Suarez A., and Palacios J. β-catenin expression pattern, β-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn. Mol. Pathol. 10 (2001) 116-122
37. Mulholland D.J., Dedhar S., Wu H., and Nelson C.C. PTEN and GSK3beta: Key regulators of progression to androgen-independent prostate cancer. Oncogene 25 (2006) 329-337
38. Nagy A., Gertsenstein M., Vintersten K., and Behringer R. Manipulating the Mouse Embryo: A Laboratory Manual (2003), Cold Spring Harbor Laboratory Press, New York
39. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix-Trench G., Thomas E.J., and Campbell I.G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58 (1998) 2095-2097
40. Oda K., Stokoe D., Taketani Y., and McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65 (2005) 10669-10673
41. Orsulic S., Li Y., Soslow R.A., Vitale-Cross L.A., and Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1 (2002) 53-62
42. Otsuka J., Okuda T., Sekizawa A., Amemiya S., Saito H., Okai T., Kushima M., and Tachikawa T. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Med. Electron Microsc. 37 (2004) 188-192
43. Powis G., Ihle N., and Kirkpatrick D.L. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin. Cancer Res. 12 (2006) 2964-2966
44. Risinger J.I., Hayes K., Maxwell G.L., Carney M.E., Dodge R.K., Barrett J.C., and Berchuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer Res. 4 (1998) 3005-3010
45. Sagae S., Kobayashi K., Nishioka Y., Sugimura M., Ishioka S., Nagata M., Terasawa K., Tokino T., and Kudo R. Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: Frequent mutations in endometrioid carcinomas. Jpn. J. Cancer Res. 90 (1999) 510-515
46. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
47. Schuijer M., and Berns E.M. TP53 and ovarian cancer. Hum. Mutat. 21 (2003) 285-291
48. Schwartz D.R., Kardia S.L., Shedden K.A., Kuick R., Michailidis G., Taylor J.M., Misek D.E., Wu R., Zhai Y., Darrah D.M., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 62 (2002) 4722-4729
49. Scully R.E., Young R.H., and Clement P.B. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Atlas of Tumor Pathology. Third Series, Fascicle 23 (1998), Armed Forces Institute of Pathology, Washington, D.C.
50. Shibata H., Toyama K., Shioya H., Ito M., Hirota M., Hasegawa S., Matsumoto H., Takano H., Akiyama T., Toyoshima K., et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278 (1997) 120-123
51. Sieben N.L., Macropoulos P., Roemen G.M., Kolkman-Uljee S.M., Jan Fleuren G., Houmadi R., Diss T., Warren B., Al Adnani M., De Goeij A.P., et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 202 (2004) 336-340
52. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21 (1999) 70-71
53. Suzuki A., Yamaguchi M.T., Ohteki T., Sasaki T., Kaisho T., Kimura Y., Yoshida R., Wakeham A., Higuchi T., Fukumoto M., et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14 (2001) 523-534
54. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., Li J., Parsons R.E., and Ellenson L.H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57 (1997) 3935-3940
55. Thomas G.V., Horvath S., Smith B.L., Crosby K., Lebel L.A., Schrage M., Said J., De Kernion J., Reiter R.E., and Sawyers C.L. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin. Cancer Res. 10 (2004) 8351-8356
56. Thompson J.E., and Thompson C.B. Putting the rap on Akt. J. Clin. Oncol. 22 (2004) 4217-4226
57. Vercellini P., Trecca D., Oldani S., Fracchiolla N.S., Neri A., and Crosignani P.G. Analysis of p53 and ras gene mutations in endometriosis. Gynecol. Obstet. Invest. 38 (1994) 70-71
58. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
59. Wright K., Wilson P., Morland S., Campbell I., Walsh M., Hurst T., Ward B., Cummings M., and Chenevix-Trench G. beta-catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int. J. Cancer 82 (1999) 625-629
60. Wu R., Zhai Y., Fearon E.R., and Cho K.R. Diverse Mechanisms of beta-Catenin Deregulation in Ovarian Endometrioid Adenocarcinomas. Cancer Res. 61 (2001) 8247-8255
61. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., and Morrison S.J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 (2006) 475-482
62. Yuan H., Mao J., Li L., and Wu D. Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation. J. Biol. Chem. 274 (1999) 30419-30423
63. Zhai Y., Wu R., Schwartz D.R., Darrah D., Reed H., Kolligs F.T., Nieman M.T., Fearon E.R., and Cho K.R. Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am. J. Pathol. 160 (2002) 1229-1238